Print Email Facebook Twitter Puberty induction in Turner syndrome: Results of oestrogen treatment on development of secondary sexual characteristics, uterine dimensions and serum hormone levels Title Puberty induction in Turner syndrome: Results of oestrogen treatment on development of secondary sexual characteristics, uterine dimensions and serum hormone levels Author Bannink, E.M.N. van Sassen, C. van Buuren, S. de Jong, F.H. Lequin, M. Mulder, P.G.H. de Muinck Keizer-Schrama, S.M.P.F. TNO Kwaliteit van Leven Publication year 2009 Abstract Background: Besides short stature, gonadal dysgenesis leading to a lack of oestrogen is one of the main characteristics of Turner syndrome (TS). In most TS girls, puberty is induced with exogenous oestrogens. Objective: To describe the pubertal development and uterine dimensions achieved by low-dose 17β-oestradiol (17β-E2) orally started at an appropriate age. Additionally, to determine whether serum hormone levels aid evaluation of pubertal progression. Design: In 56 TS girls, we prospectively studied pubertal stage, serum E2, LH, FSH, SHBG and oestrone (E1), starting oestrogen treatment with a low-dose 17β-E2 (5 μg/kg/day) during GH treatment at mean (SD) age 12.7 (0.7) years. Hormone levels were measured at start, 3 months after start and after increasing 17β-E2 dosage. Uterine dimensions were measured in 39 TS women at age 19.9 (2.2) years. Results: Although breast and pubic hair development were similar to that in normal Dutch girls up to Tanner stage B5 and P5, respectively, breast development was 2 years later. Before oestrogen therapy, E2 levels were comparable to those in prepubertal girls. With a 17β-E2 dose of 5 μg/kg/day, these levels increased significantly, becoming comparable to normal late pubertal or adult concentrations, whereas SHBG levels were unchanged. At the adult 17β-E2 dose, SHBG had increased significantly. Uterus shape was juvenile in four (10.2%), cylindrical in four and mature-adult shaped in 31 (79.5%) of TS patients. Conclusions: During GH treatment in TS girls, normal breast development up to B5 can be mimicked, with just a 2-year delay. In a clinical setting, serum hormone levels provide no additional information for evaluating pubertal progression. After age-appropriate pubertal induction, uterine dimensions in women aged nearly 20 years were subnormal. It remains unclear whether this was related to E2 dosage, timing or duration, or factors related to TS. © 2009 The Authors. Subject HealthLeefomgeving en gezondheidEstradiolEstroneFollitropinLuteinizing hormoneSex hormone binding globulinAdolescentAdultBreast developmentChildControlled studyEstrone blood levelFemaleFollitropin blood levelHumanLow drug doseLuteinizing hormone blood levelMajor clinical studyPubertySchool childTurner syndromeultrasoundAdministration, OralAdolescentBreastChildCross-Sectional StudiesDose-Response Relationship, DrugEstradiolEstrogensFollicle Stimulating HormoneFollow-Up StudiesHumansLuteinizing HormoneProspective StudiesPubertySex CharacteristicsSex Hormone-Binding GlobulinTurner SyndromeUterusYoung Adult To reference this document use: http://resolver.tudelft.nl/uuid:0f71f379-5256-4de2-a475-49452797d263 TNO identifier 278460 Source Clinical Endocrinology, 70 (2), 265-273 Document type article Files To receive the publication files, please send an e-mail request to TNO Library.